Jaguar Health, Inc.
Company & revenue
About Jaguar Health, Inc.
Who they are
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy.
Detailed revenue, brand and relationship research has not yet been completed for JAGX.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
21
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
11
Poor
Financial Strength
19
Business Quality / Moat
0
Management
13
Growth Quality
21
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
25
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
30/100
Building Historical Record
Model Score 30/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Severe debt stress
- •Reverse-split headline · Sep 15, 2026
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for JAGX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can JAGX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is JAGX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is JAGX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for JAGX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify JAGX's current valuation?
Essential Investment Snapshot
Wall Street Score
21
Opportunity Score
25
Market Cap
$1.6M
P/E Ratio
-0.0
EPS
$-5482.20
52-Week High
$1267.88
52-Week Low
$2.35
Beta
-0.05
Analyst Target
$3.21
Shares Outstanding
434K
Total Revenue
$27.8M
Total Debt
$16.7M
Dividend
No current dividend
Liquidation Value / Share
$11.34
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for JAGX
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x
Reverse-split headline · Sep 15, 2026
Jaguar Health, Inc. Announces Reverse Stock Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
AccesswireCommunity Sentiment
0 active · 0 total callsNo personal call yet on JAGX.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral th.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Diluted weighted-average shares increased 2690.5% year over year.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
16
Jul 24, 2026
Change
+4.8
points
Current Score
21
Oct 1, 2026
Category Changes
JAGX increased 4.8 points because Revenue improved by 13.1 points, Asset improved by 55 points, Buffett improved by 4.5 points.
Positive Contributors
- + Revenue improved by 13.1 points
- + Asset improved by 55 points
- + Buffett improved by 4.5 points
Negative Contributors
- − Debt declined by 10.3 points
- − Management declined by 25 points
Projected Score
Projected Score
17
Projected Change
-4.0%
Preliminary comparable-period financial changes suggest decline of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.66
Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Related Companies
BiotechnologyNews
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
Jaguar Health Stock Surges Friday: What's Happening?
Jaguar Health Stock Slides Thursday: What's Happening?
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial